Despite raising the price of its IPO twice, Caris Life Sciences Inc. left money on the table with a 33% increase in price as ...

Caris Life Sciences is experiencing rapid growth, leveraging AI and molecular science for personalized medicine. Click here ...

Caris Life Sciences (CAI) priced 23.53M shares at $21.00. The deal priced above the $19.00-$20.00 range. BofA, JPMorgan and Goldman Sachs acted as joint book running managers for the offering. Caris ...

Recent developments in health include Brazil's bird flu impacts harming its chicken exports, new weight-loss drugs focusing ...

Recent health news highlights include global bird flu restrictions impacting Brazilian chicken exports, advancements in ...

Caris Life Sciences shares ended trading at $28 per share on Wednesday, marking a 33% increase from its initial public offering (IPO) price of $21 per share.

Cancer-testing company raises $494 million in initial public offering.

Caris Life Sciences raised $494.1 million in its Nasdaq initial public offering, the cancer diagnostic firm said on Tuesday, ...

Caris plans to use the proceeds from its IPO to pay off about $400 million worth of debt, he noted, and it also intends to use the funds to drive toward profitability next year and continue expanding ...

The stock of Caris Life Sciences shined in its Nasdaq debut on Wednesday, pricing its heavily-subscribed initial public ...

The Dow Jones Industrial Average ended Wednesday (June 18) modestly lower following the Federal Reserve’s latest policy ...

The successful IPO of Caris Life Sciences makes its founder David Dean Halbert worth an estimated $3.3 billion.